Page 24 - Serum Institute Of India

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Expects to complete trials by year-end

Expert committee on Covid-19 vaccine administration to meet on Wednesday

The Serum Institute of India, Pune has also been permitted for conducting Phase 2 and 3 human clinical trials of the Oxford University-developed Covid-19 vaccine

India weighs options in debate on who gets first shot of Covid-19 vaccine

Companies wait for government orders as top medical research group says health workers must get first inoculation

Serum Institute to provide Covid vaccine to 92 countries at Rs 250 a dose

Partners with Gavi, Gates Foundation, will provide 100 mn doses to Covax, a WHO initiative led by Gavi and CEPI

Serum Institute to price Covid-19 vaccine at less than Rs 250/dose in India

As per SII, the vaccines will be available as early as the first half of 2021 after gaining approvals and qualifications from the WHO

Novavax signs Covid-19 vaccine supply deal with India's Serum Institute

The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal

'Our sort of moment': Indian billionaires bet big in Covid-19 vaccine race

Serum Institute, the world's largest vaccine producer, has announced a plan to make hundreds of millions of doses of an unproven inoculation. 'I hope we don't go in too deep,' says CEO Adar Poonawalla

More than enough doses of Covid-19 vaccine reserved for Parsis: Poonawalla

Serum Institute CEO didn't specify quantity of doses to be kept for community grappling with shrinking population

Oxford Covid-19 vaccine trials in India: Serum Institute seeks DCGI nod

Initial results of the first two-phase trials of the vaccine conducted in five trial sites in the UK showed it has an acceptable safety profile and homologous boosting increased antibody responses

Adar Poonawalla: A rare risk-taking CEO with strong business acumen

Adar Poonawalla's Serum Institute has tied up with AstraZeneca-backed Oxford vaccine candidate for one billion doses which it will make for India and the GAVI vaccine alliance of 58 countries

Hotspots Mumbai, Pune to help test vaccine efficacy: Serum Institute

The high prevalence of COVID-19 infections in Mumbai and Pune will help test the efficacy of the vaccine developed by Oxford University and AstraZeneca, its local manufacturer SSI said

Govt to ensure regulatory facilitation for Serum's Covid-19 vaccine trials

Serum Institute of India, the largest vaccine manufacturer in the world, has been chosen by Oxford and its partner AstraZeneca to manufacture the vaccine once it gets ready.

We want to price Covid-19 vaccine below Rs 1,000: Serum Institute CEO

Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222

Serum Institute to begin trials of Oxford's Covid-19 vaccine by August-end

The varsity has tied up with Serum Institute of India (SII) to manufacture and supply the vaccine to India and over 60 other countries having a combined population of 3 billion

Serum Institute to apply for trials on Oxford's Covid-19 vaccine soon: CEO

SII, the largest vaccine manufacturer in the world, has been chosen by Oxford and its partner AstraZeneca to manufacture the vaccine once it gets ready

Indian pharma can produce Covid-19 vaccines for entire world: Bill Gates

India's challenge immense in coronavirus crisis immense because of its large population, says billionaire philanthropist

Serum Institute of India expects to develop Covid-19 vaccine by year-end

Poonawalla further said that till the vaccine comes, testing is the key and that is why SII has invested in MyLabs

Covid-19 crisis: Race to develop vaccine gets a booster as field widens

On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.

Jeff Bezos, Mukesh Ambani rise in wealth report on coronavirus times

China-based Hurun Research's report tracks wealth changes of successful entrepreneurs in the four months ending May 31.

Shot of Hope: Equal access a hurdle after race to coronavirus vaccine

The second of a two-part series examines challenges linked to IPR and monopoly once Covid-19 vaccine is created